HealthSource

What you're buying

HealthSource sells three weight-loss products, and a good deal else besides. On the weight side there is compounded semaglutide as a weekly injection, compounded tirzepatide as a weekly injection, and an oral tirzepatide tablet you place under the tongue at bedtime and let dissolve. The same storefront also sells sermorelin, glutathione, NAD+ by injection and by nasal spray, generic sildenafil and tadalafil, Addyi and Upneeq eye drops. It is a general telehealth shop with a GLP-1 aisle rather than a weight clinic, and the shopping-cart mechanics are the first thing you notice.

The company calls itself a platform, not a practice. Prescribing runs through MD Integrations, a physician network whose chief executive, Dr. Marc Serota, is named on the medical practitioners page and described as licensed in 45 states; that same page says plainly that individual practitioners are not publicly listed, so you will not learn who wrote your prescription until you are inside the portal. The pharmacy is easier to pin down than the marketing language suggests. Product pages say only "our trusted US-based FDA 503A licensed partner pharmacy", but the contact page publishes a pharmacist phone line and a dispensing address for it, at 1 Tower Center Blvd in East Brunswick, New Jersey, together with a pharmacy care email on the dirxhealth.com domain. A site that names its compounder in the fine print and hides it in the sales copy is doing the right thing in the wrong order.

What it costs (and how it's billed)

Read the prices slowly, because the unit is not the month. Every weight-loss product here is charged "every 4 weeks". Compounded semaglutide is $199 every four weeks, and it is the same figure at the starter supply and at the full dose. Compounded tirzepatide is $299 every four weeks on the same flat basis. The sublingual tirzepatide tablet is $399 every four weeks. There is no membership, no separate consultation charge and no shipping fee; the price covers the medication, the supplies and the telehealth visit.

Four weeks is not a month, and across a year the gap is real. Thirteen charges rather than twelve means the semaglutide plan comes to $2,587 a year and the tirzepatide plan to $3,887 a year, roughly 8% above what the same numbers would cost if they were calendar-month rates. Nothing on the site does that arithmetic for you. The sales copy says "monthly telehealth visits" and "the current month's program" while the checkout says every 4 weeks, and only one of those is what your card sees.

There is a cheaper rung, and the site does not advertise it as one. Each injection also comes as an eight-week supply: $349 every eight weeks for semaglutide and $549 every eight weeks for tirzepatide. That is about $175 for every four weeks of semaglutide and about $275 for every four weeks of tirzepatide, a genuine saving of roughly 12% on identical medication. It sits in a dropdown labeled Initial Supply, which most buyers will read as a starter-size choice rather than a price tier, so the discount goes to whoever happens to click it.

Refunds are narrow and worth knowing before you pay. Cancel before the intake form is filled in and you get everything back. Fill it in and then withdraw, and HealthSource keeps a $25 to $45 fee for the telemedicine consultation it says has already taken place. Once a clinician approves the prescription and the pharmacy has the order, nothing is refundable at all, and canceling a subscription only stops the next cycle: the one you are in has been paid for and is not prorated.

Who can order

The service areas page is unusually blunt. All 50 states, Alaska and Hawaii included, and nothing outside them, with US territories and international addresses ruled out by name. MD Integrations says its own network reaches all 50 states, Washington DC and Guam, so the narrower line is a rule HealthSource has chosen rather than a licensing limit it has run into. You must be at least 18.

The clinical exclusions are published before you order, in a short knowledge-base article, and they are more specific than most sellers bother with: no pregnancy or breastfeeding, no uncontrolled substance use disorder, none of anorexia nervosa, bulimia nervosa or binge eating disorder, no bariatric surgery in the previous six months, no active or chronic cholecystitis (a removed gallbladder is fine), no pancreatitis in the last six months and no history of pancreatitis caused by a GLP-1, no personal or family history of medullary thyroid cancer, no MEN2 syndrome, no active and uncontrolled diabetes, no diabetic retinopathy. What is missing is a body mass index threshold, and any mention of lab work at all. No baseline blood panel is asked for anywhere on the site, before treatment or during it.

How the intake works

This is the part to understand before you start, because HealthSource runs it in the opposite order to most of its competitors. You pick a product, you check out, and the link to the medical questionnaire appears on the thank-you page afterward. The site says so in as many words: answer the questionnaire "after placing your order". A licensed physician then reviews it, with same-day review advertised, and the injection ships in three to five business days from the New Jersey pharmacy. The sublingual tablet is quoted at five to ten business days, which is a long wait for a tablet.

After that, everything runs through a patient portal on the MD Integrations side. Unlimited messaging with the prescribing clinician is included, dose changes are handled there, and the subscription carries an automatic refund if the reassessment due each cycle is not completed, which is a real safeguard: it stops a plan renewing on a patient nobody has looked at. Support is by email at info@healthsource.online and by phone on a New York number.

What we'd want changed

Take the money after a clinician has read the intake, not before it. Charging the card first puts a new patient at risk of a $25 to $45 consultation deduction on the strength of criteria the site itself publishes and the patient may fail, and it quietly turns the free-sounding same-day telehealth review into something already bought. The second half of the same fix is to print "every four weeks" beside the price rather than only at checkout. Thirteen charges a year is a perfectly defensible way to sell a weekly injection; letting a reader believe it is twelve is not.

Two smaller things. The weight-loss pages carry a row of statistics, 95% of participants losing significant weight, 15% of body weight on average, a 65% lower risk of type 2 diabetes, with no study named beside any of them, on a page selling a compounded drug. Name the trials or take the numbers down. And the promise of 24/7 care-team access sits on the same site as a contact page publishing hours of Monday to Friday, 9am to 6pm, and Saturday 10am to 4pm. Only one of those is the real answer, and a patient with a 2am side effect deserves to know which.

Bottom line

HealthSource is more transparent than its plain storefront makes it look. The pharmacy has an address and a phone number, the physician network has a name, the exclusion list is published where you can read it before paying, a LegitScript seal is displayed, and $199 and $299 buy the same medication at your starting dose and at your full dose. What those numbers are not is a monthly price. Budget for thirteen charges a year, take the eight-week supply if you already know the medication agrees with you, and go in knowing that filling in the questionnaire costs you $25 to $45 in consultation fees whether or not you are approved, and that once the pharmacy has the order none of it comes back.